WASHINGTON (Reuters) – Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push “Dermagraft,” a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.